These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [New development in the treatment of breast cancer. II. Future anti-HER2 therapy]. Yamashita T; Iwata K Gan To Kagaku Ryoho; 2009 Dec; 36(13):2551-4. PubMed ID: 20104676 [No Abstract] [Full Text] [Related]
23. The use of immunotherapy in the first-line treatment of lung cancer. Rizvi NA Clin Adv Hematol Oncol; 2017 Mar; 15(3):190-192. PubMed ID: 28398273 [No Abstract] [Full Text] [Related]
24. Pembrolizumab plus Chemotherapy in Lung Cancer. Diker O N Engl J Med; 2018 Sep; 379(11):e18. PubMed ID: 30211501 [No Abstract] [Full Text] [Related]
25. Pembrolizumab plus Chemotherapy in Lung Cancer. Sun R; Rich MW; Wei LJ N Engl J Med; 2018 Sep; 379(11):e18. PubMed ID: 30211499 [No Abstract] [Full Text] [Related]
26. One-pot access to indolo[2,3-b]quinolines by electrophile-triggered cross-amination/Friedel-Crafts alkylation of indoles with 1-(2-tosylaminophenyl)ketones. Ali S; Li YX; Anwar S; Yang F; Chen ZS; Liang YM J Org Chem; 2012 Jan; 77(1):424-31. PubMed ID: 22136250 [TBL] [Abstract][Full Text] [Related]
27. Heterocycle annulation of enolizable vinyl quinone imides. Dihydroquinolines and quinolines from thermal 6pi-electrocyclizations and indoles from photochemical cyclizations. Parker KA; Mindt TL Org Lett; 2002 Nov; 4(24):4265-8. PubMed ID: 12443074 [TBL] [Abstract][Full Text] [Related]
28. Hydrogenated benzo[f]quinolines and benz[e]indoles as analgetics. 1. Takeda M; Konda M; Honma Y; Inoue H; Saito S J Med Chem; 1975 Jul; 18(7):697-9. PubMed ID: 1151991 [TBL] [Abstract][Full Text] [Related]
33. Cleavage of C-C Bonds for the Synthesis of C2-Substituted Quinolines and Indoles by Catalyst-Controlled Tandem Annulation of 2-Vinylanilines and Alkynoates. Ni J; Jiang Y; An Z; Yan R Org Lett; 2018 Mar; 20(6):1534-1537. PubMed ID: 29517239 [TBL] [Abstract][Full Text] [Related]
34. Synthesis of indolylquinolines, indolylacridines, and indolylcyclopenta[b]quinolines from the Baylis-Hillman adducts: an in situ [1,3]-sigmatropic rearrangement of an indole nucleus to access indolylacridines and indolylcyclopenta[b]quinolines. Ramesh C; Lei PM; Janreddy D; Kavala V; Kuo CW; Yao CF J Org Chem; 2012 Oct; 77(19):8451-64. PubMed ID: 22967265 [TBL] [Abstract][Full Text] [Related]
35. Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective. Girard N Expert Rev Anticancer Ther; 2013 Oct; 13(10):1193-206. PubMed ID: 24134421 [TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer. Rosell R; Ito M Lancet Oncol; 2020 Jun; 21(6):736-738. PubMed ID: 32386569 [No Abstract] [Full Text] [Related]
38. Immune checkpoint inhibitors in lung cancer: an update. Sullivan K; Preeshagul I; Budman D; Seetharamu N Future Oncol; 2017 May; 13(11):955-959. PubMed ID: 28481150 [No Abstract] [Full Text] [Related]
39. An efficient iron-promoted synthesis of 6H-indolo[2,3-b]quinolines and neocryptolepine derivatives. Yan Z; Wan C; Wan J; Wang Z Org Biomol Chem; 2016 May; 14(19):4405-8. PubMed ID: 27117399 [TBL] [Abstract][Full Text] [Related]
40. [Chinese expert consensus on Anlotinib Hydrochloride for advanced lung cancer (2020 edition)]. ; ; Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):807-816. PubMed ID: 33113621 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]